We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00032747
Recruitment Status : Completed
First Posted : April 1, 2002
Last Update Posted : June 17, 2008
Information provided by:

Brief Summary:
This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration study. Randomization will be stratified according to the patient's baseline serum sodium concentration (137-144 and <137 mmol/L). The dose of study drug will be increased to the next level on Day 15, and the total duration of the double-blind treatment period is 120 days.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure Drug: Vasopressin V2 Receptor Antagonist Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 338 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure
Study Start Date : August 2001
Study Completion Date : February 2003

Primary Outcome Measures :
  1. Clinical status at day 120.

Secondary Outcome Measures :
  1. NYHA functional class, left ventricular ejection fraction, global assessment,serum sodium concentration.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Men or women with chronic heart failure (NYHA Class IIIB and IV).
  • Women must be post-menopausal or surgically sterilized; they cannot be pregnant or nursing.
  • Age 21 to 80 years.
  • Chronic heart failure of at least 3 months duration. For 2 months prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 50% of the time. For 2 weeks prior to screening, patients must have had symptoms at rest or on minimal exertion for more than 90% of the time.
  • Patients must be receiving a diuretic and an ACE inhibitor (or an angiotensin II receptor antagonist) for the treatment of heart failure.
  • Patients may be receiving digoxin, a beta-blocker or spironolactone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00032747

United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, Iowa
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States, 52242-1081
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
United States, Nebraska
Brian LGH Heart Institute
Lincoln, Nebraska, United States, 68510
United States, Ohio
The Lindner Clinical Trial Center
Cincinnati, Ohio, United States, 45219
United States, South Carolina
MUSC/Division Cardiology
Charleston, South Carolina, United States, 29425
Sanofi-aventis Administrative Office
Laval, Canada
United Kingdom
Sanofi-aventis Administrative Office
Guildford Surrey, United Kingdom
Sponsors and Collaborators
Study Director: ICD CSD Sanofi

Additional Information:
Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00032747     History of Changes
Other Study ID Numbers: DFI4510
First Posted: April 1, 2002    Key Record Dates
Last Update Posted: June 17, 2008
Last Verified: June 2008

Keywords provided by Sanofi:
Chronic Heart Failure
Heart Disease

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Arginine Vasopressin
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs